Stock comparison

BMYvsRGC

Bristol-Myers Squibb CovsRegencell Bioscience Holdings Ltd. Real data pulled from the alphactor.ai fundamentals pipeline — valuation, balance-sheet health, momentum, and analyst sentiment side by side.

BMY

Bristol-Myers Squibb Co

$59.02

+8.71%

Pharmaceuticals$117.4BNYSE

RGC

Regencell Bioscience Holdings Ltd

$28.31

+70.54%

Pharmaceuticals$11.9BNASDAQ

60-day price, rebased to 100

BMY +8.73% · RGC -12.33%

Round-by-round

BMY 3·RGC 1· 2ties

Tie

Valuation upside

+2.90% vs — to DCF fair value

EdgeRGC

Balance-sheet strength

Altman Z 2.20 vs 32636.93

EdgeBMY

Fundamental quality

Piotroski 9.00 vs 4.00 (of 9)

Tie

Growth + margins

Rule-of-40 26.40 vs —

EdgeBMY

60-day momentum

+8.73% vs -12.33% price return

EdgeBMY

Market-cap liquidity

$117.4B vs $11.9B

Verdict

Across6categories,BMYtakes the edge with3wins to1 (and 2 ties). Neither score is a buy signal on its own: run the full backtest and credibility tests on alphactor.ai before putting money on it.

Backtest a strategy onBMYorRGC

Point-in-time backtests, 8-layer credibility pipeline, conviction scoring — free to start.